Precision AQ
Amidst growing pressure on life sciences companies to produce financial results alongside innovative treatments, the demand for a unified provider to assist in bringing new medications to market has never been more critical. Precision Value & Health, a leading figure in guiding life sciences firms through the intricacies of commercialization, was ready to fulfill this role. The CEO aimed to create the world’s sole comprehensive solution for the entire drug commercialization process through several acquisitions, thus forming a new market category. To succeed, the company needed to integrate its broadened services into a cohesive offering that could compete effectively in a crowded marketplace. Additionally, it was crucial to consolidate employees after mergers and acquisitions into a single, driven workforce. Our research highlighted that companies in this space commonly emphasized the notion of marketplace access, to the point where the term "access" had lost its impact. To forge a stronger connection with customers, we redefined access to establish a new category. Moving forward, access would encompass more than just market entry; it would signify providing pharmaceutical companies with improved data, superior personnel, and enhanced processes, ultimately giving patients pathways to vital new treatments. This reorientation led us to create a brand centered on a fresh purpose: empowering access to life-changing medicine for everyone. To reinforce this purpose-driven brand, we introduced a new name: Precision AQ. This name, representing Precision Access Quotient, captures the organization’s mission to eliminate barriers by blending scientific (IQ) and empathetic (EQ) approaches. The result is “AQ: Access Quotient,” an essential factor in managing the journey from therapy to patient, driven by data-led analytics and insights. It’s a new name that embodies a new mindset… in a brand new category. Explore the full case study: https://www.desantisbreindel.com/work/precision-aq/